Inflammatory plasma biomarkers in subjects with preclinical Alzheimer's disease.
3 August 2022. doid: 10.1186/s13195-022-01051-2
Prins S, de Kam ML, Teunissen CE, Groeneveld GJ
View publicationThis study investigated plasma biomarkers for neuroinflammation associated with Alzheimer's disease (AD) in subjects with preclinical AD compared to healthy elderly. How these biomarkers behave in patients with AD, compared to healthy elderly is well known, but determining these in subjects with preclinical AD is not and will add information related to the onset of AD. When found to be different in preclinical AD, these inflammatory biomarkers may be used to select preclinical AD subjects who are most likely to develop AD, to participate in clinical trials with new disease-modifying drugs.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
